In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
A phase 2 clinical trial found that ataciguat, a soluble guanylate cyclase activator, may slow aortic valve calcification and help preserve cardiac function in patients with moderate calcific aortic valve...
A phase 2 clinical trial found that ataciguat, a soluble guanylate cyclase activator, may slow aortic valve calcification and help preserve cardiac function in patients with moderate calcific aortic valve...
